We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

107 hedge funds and large institutions have $62.4M invested in Aclaris Therapeutics in 2023 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 41 increasing their positions, 26 reducing their positions, and 53 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 26

35% more call options, than puts

Call options by funds: $97K | Put options by funds: $72K

14.9% less ownership

Funds ownership: 98.84% → 83.94% (-15%)

22% less funds holding

Funds holding: 137 → 107 (-30)

55% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 53

87% less capital invested

Capital invested by funds: $480M → $62.4M (-$418M)

100% less funds holding in top 10

Funds holding in top 10: 4 → 0 (-4)

Holders
107
Holders Change
-30
Holders Change %
-21.9%
% of All Funds
1.56%
Holding in Top 10
–
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-100%
% of All Funds
–
New
24
Increased
41
Reduced
26
Closed
53
Calls
$97K
Puts
$72K
Net Calls
+$25K
Net Calls Change
-$6.32M

Top Buyers

1
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$7.17M
2
Citadel Advisors
Citadel Advisors
Florida
+$6.2M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$5.71M
4
VCIM
Velan Capital Investment Management
Georgia
+$5.37M
5
TCM
Tang Capital Management
California
+$5.35M

Top Sellers

1
BI
BVF Inc
California
-$48.4M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$47.8M
3
RCM
RA Capital Management
Massachusetts
-$30.1M
4
FCMI
Foresite Capital Management IV
California
-$19.2M
5
GPP
Great Point Partners
Connecticut
-$11.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$547K +$757K +248,059 +91%
Citigroup
27
Citigroup
New York
$533K +$1.51M +495,644 +4,178%
CC
28
Checkpoint Capital
California
$476K +$1.38M +453,614 New
N
29
Nuveen
North Carolina
$462K -$62.3K -20,412 -4%
Charles Schwab
30
Charles Schwab
California
$458K -$82.1K -26,904 -6%
ACM
31
Aisling Capital Management
New York
$456K – – –
XT
32
XTX Topco
Cayman Islands
$397K +$1.15M +378,300 New
HighTower Advisors
33
HighTower Advisors
Illinois
$361K -$81.7K -26,778 -7%
Bank of New York Mellon
34
Bank of New York Mellon
New York
$296K +$121K +39,601 +16%
FLSM
35
Frazier Life Sciences Management
California
$278K – – –
Jane Street
36
Jane Street
New York
$272K +$291K +95,324 +58%
BNP Paribas Financial Markets
37
BNP Paribas Financial Markets
France
$228K +$429K +140,744 +184%
SO
38
STRS Ohio
Ohio
$202K +$424K +138,900 +257%
Dimensional Fund Advisors
39
Dimensional Fund Advisors
Texas
$197K -$226K -74,180 -28%
Barclays
40
Barclays
United Kingdom
$185K -$178K -58,231 -25%
Susquehanna International Group
41
Susquehanna International Group
Pennsylvania
$161K +$90.8K +29,759 +24%
ECM
42
Endurant Capital Management
California
$156K +$453K +148,400 New
CS
43
Credit Suisse
Switzerland
$142K +$111K +36,522 +37%
CSS
44
Cubist Systematic Strategies
Connecticut
$142K +$282K +92,271 +214%
Bank of America
45
Bank of America
North Carolina
$132K +$225K +73,689 +143%
LPC
46
Lion Point Capital
New York
$122K – – –
UBS AM
47
UBS AM
Illinois
$119K – – –
Swiss National Bank
48
Swiss National Bank
Switzerland
$114K – – –
T. Rowe Price Associates
49
T. Rowe Price Associates
Maryland
$114K -$65.2K -21,372 -16%
Man Group
50
Man Group
United Kingdom
$106K +$309K +101,280 New
1
2
3 4 5

ACRS Hedge Fund Activity: Q4 2023 in Review

107 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q4 2023, worth a combined $62.4M — down 87% from $480M a quarter earlier.

Sellers outnumbered buyers: 53 funds closed out of ACRS and 24 opened new positions — a net loss of 29 holders — while 26 trimmed existing stakes and 41 added.

The largest buyer was Acadian Asset Management, opening a new position worth an estimated $7.17M. The largest seller was BVF Inc, exiting entirely with an estimated $48.4M sold.

  • 107 institutional investors held Aclaris Therapeutics (ACRS) as of Q4 2023, down from 137 in Q3 2023.
  • Funds reported $62.4M of Aclaris Therapeutics stock for Q4 2023, down 87% quarter-over-quarter.
  • 24 funds opened new Aclaris Therapeutics positions in Q4 2023 and 53 closed out, a net change of -29 holders.
  • The largest Aclaris Therapeutics buyer in Q4 2023 was Acadian Asset Management, an estimated $7.17M added.
  • The largest Aclaris Therapeutics seller in Q4 2023 was BVF Inc, an estimated $48.4M sold.

Based on aggregated 13F filings for Q4 2023.